Part 2 – Case Discussion
Daniel A. Pollyea, MD, MS, presents the case of patient “N.K.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).
Click here to learn more by viewing Part 3 – Case Discussion & Wrap-up.
Disclosures: Brian A. Jonas, MD, PhD, FACP Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC Travel Reimbursement: AbbVie Gabriel N. Mannis, MD Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz Daniel A. Pollyea, MD, MS Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas References:
- Otoukesh S, Zhang J, Nakamura R, Stein AS, Forman SJ, et alI. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leuk Lymphoma. 2020 Aug;61(8):2020-2023. doi: 10.1080/10428194.2020.1742908. Epub 2020 Mar 19. PMID: 32191144.
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.
